Qlife Holding Correlations
The current 90-days correlation between Qlife Holding AB and Fluicell AB is 0.14 (i.e., Average diversification). The correlation of Qlife Holding is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Qlife |
The ability to find closely correlated positions to Qlife Holding could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Qlife Holding when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Qlife Holding - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Qlife Holding AB to buy it.
Moving together with Qlife Stock
Moving against Qlife Stock
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Qlife Stock performing well and Qlife Holding Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Qlife Holding's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
FLUI | 3.75 | (0.81) | 0.00 | 3.33 | 0.00 | 8.58 | 27.23 | |||
M8G | 2.49 | 0.24 | 0.04 | 1.59 | 2.95 | 4.99 | 19.46 | |||
EXPRS2 | 4.58 | (0.61) | 0.00 | (0.39) | 0.00 | 8.60 | 59.10 | |||
SANION | 5.78 | 1.54 | 0.14 | (0.60) | 6.62 | 10.73 | 95.94 |
Qlife Holding Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Qlife Holding stock to make a market-neutral strategy. Peer analysis of Qlife Holding could also be used in its relative valuation, which is a method of valuing Qlife Holding by comparing valuation metrics with similar companies.
Risk & Return | Correlation |
Qlife Holding Corporate Management
Elected by the shareholders, the Qlife Holding's board of directors comprises two types of representatives: Qlife Holding inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Qlife. The board's role is to monitor Qlife Holding's management team and ensure that shareholders' interests are well served. Qlife Holding's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Qlife Holding's outside directors are responsible for providing unbiased perspectives on the board's policies.
Jakob Lind | Global Clinical | Profile | |
Thomas Warthoe | CEO CoFounder | Profile | |
Peter Warthoe | CoFounder Officer | Profile | |
Kasper Rousoe | Chief Officer | Profile |